Fulcrum Therapeutics Halts Sickle Cell Drug Development Following Cancer Risk Concerns

Fulcrum Therapeutics announced on Tuesday that it is discontinuing the development of its lead sickle cell disease asset, a decision that triggered a corporate reorganization and caused the company’s stock price to drop by more than 50% in morning trading. The company halted the program following concerns regarding potential cancer risks associated with the drug’s therapeutic class.

The decision follows a recent industry-wide shift regarding this class of medications. In March, Ipsen withdrew its drug Tazverik—which shares the same chemical classification as the Fulcrum asset—from the market after identifying a risk of secondary malignancies in patients. Fulcrum Therapeutics is now restructuring its business operations in response to the termination of the program.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI